Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
Open Access
- 9 August 2005
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (5) , 510-514
- https://doi.org/10.1038/sj.bjc.6602733
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal CarcinomaJournal of Clinical Oncology, 2004
- Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal CancersClinical Colorectal Cancer, 2004
- Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal CarcinomaClinical Colorectal Cancer, 2004
- Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.2003
- Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III StudyJournal of Clinical Oncology, 2001
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III StudyJournal of Clinical Oncology, 2001
- Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancerAnnals of Oncology, 2000
- A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.Cancer Investigation, 1999